)
Autolus Therapeutics (AUTL) investor relations material
Autolus Therapeutics 25th Annual Needham Virtual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Recent developments and product differentiation
Focus on CAR-T therapies with high clinical activity and strong safety profile, aiming for broad patient access in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL).
AUCATZYL (obe-cel) is available in the U.S. and U.K., with ongoing efforts for European market access.
Real-world data from the Rocket Consortium supports robust efficacy and safety, with a reliable supply chain and high manufacturing success rates.
Market opportunity and patient impact
U.S. addressable market for relapsed/refractory adult ALL is about 1,800 patients annually, with high unmet medical need.
Disease progression can severely impact cognition and mobility, highlighting the need for effective therapies.
Efficacy and safety profile
Pivotal study showed a 78% overall response rate, with 40% of patients in ongoing remission after three years.
Real-world response rates are even higher at 95%, especially in patients treated earlier in disease progression.
High-grade cytokine release syndrome was not observed, and only 3% experienced high-grade neurological toxicity, enabling treatment of frail or high-risk patients.
- AUCATZYL drives revenue and clinical success, with pipeline growth in oncology and autoimmune diseases.AUTL
Corporate presentation13 Apr 2026 - Shelf registration enables up to $150M in securities to fund T cell therapy growth and expansion.AUTL
Registration filing13 Apr 2026 - Major shareholders are reselling 54.6M ADSs; company receives proceeds only from warrant exercises.AUTL
Registration filing13 Apr 2026 - Obe-cel achieves high efficacy and safety, supporting expanded use in frontline and pediatric ALL.AUTL
Status update13 Apr 2026 - 2025 revenue was $74.3M; 2026 guidance is $120–$135M with positive gross margin expected.AUTL
Q4 202531 Mar 2026 - Rapid market leadership and expansion into new indications drive strong growth outlook.AUTL
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Obe-cel demonstrates durable survival and safety in ALL, with launch and financial readiness secured.AUTL
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Obe-cel nears FDA decision with strong data, cash reserves, and US launch readiness.AUTL
Q2 20242 Feb 2026 - CAR T therapy shows durable remission in ALL and advances into autoimmune disease trials.AUTL
Jefferies Global Healthcare Conference1 Feb 2026
Next Autolus Therapeutics earnings date
Next Autolus Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage